Education on Increased ICP Reduces Nursing ‘Headache’

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 11
Volume 11
Issue 11

WASHINGTON-Managing the associated neurological problems of brain tumors is a crucial issue for oncology nurses, said Karen Baumgartner, MSN, APRN, BC, advance practice nurse in the Neuro Center at M.D. Anderson Cancer Center. If nurses fail to notice the signs indicating increased intracranial pressure (ICP), neurological injury and even death can result.

WASHINGTON—Managing the associated neurological problems of brain tumors is a crucial issue for oncology nurses, said Karen Baumgartner, MSN, APRN, BC, advance practice nurse in the Neuro Center at M.D. Anderson Cancer Center. If nurses fail to notice the signs indicating increased intracranial pressure (ICP), neurological injury and even death can result.

When turnover in the nursing staff left a neuro-oncology unit devoid of nurses knowledgeable in basic neurological assessment and experienced at identifying the signs and symptoms of increased intracranial pressure, an effective and convenient teaching method became imperative. A nurse-designed self-study module met the need, Ms. Baumgartner and her colleague Susan Hummel, RN, MN, CNS, reported at the Oncology Nursing Society (abstract 83) Congress.

Based on guidelines from the Brain Trauma Foundation, the module included a pretest, written instructional material, a post-test, and an evaluation form. Four experienced oncology nurses who were nonetheless new to neuro-oncology used the module in a pilot study. At pretest, the nurses correctly answered an average of only 60% of questions. After studying with the module, they averaged 90% correct. Their evaluations of the written material suggested revisions were needed to explain more specifically the pathophysiology of increased intracranial pressure. Once the module is approved for continuing education credit, it will be made available to other nurses at the facility, she said. 

Recent Videos
Data from the SPOTLIGHT and GLOW trials reveal that zolbetuximab increased survival in patients with CLDN18.2-positive gastric or GEJ adenocarcinoma.
The incorporation of zolbetuximab in addition to chemotherapy has shown benefit in patients with Claudin 18.2–positive gastric cancers in clinical trials.
Michael J. Hall, MD, MS, FASCO, discusses the need to reduce barriers to care for those with Li-Fraumeni syndrome, including those who live in rural areas.
Patrick Oh, MD, highlights next steps for further research in treating patients with systemic therapy in addition to radiotherapy for early-stage NSCLC.
The ability of metformin to disrupt mitochondrial metabolism may help mitigate the risk of cancer in patients with Li-Fraumeni syndrome.
Related Content